Get the Stockscreener App
27.97
4.23%
-1.235
After Hours:
28.36
0.39
+1.39%
Alumis Inc stock is traded at $27.97, with a volume of 1.14M.
It is down -4.23% in the last 24 hours and up +7.33% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$29.20
Open:
$28.55
24h Volume:
1.14M
Relative Volume:
0.40
Market Cap:
$3.49B
Revenue:
$22.12M
Net Income/Loss:
$-245.15M
P/E Ratio:
-7.2563
EPS:
-3.8546
Net Cash Flow:
$-373.40M
1W Performance:
+5.39%
1M Performance:
+7.33%
6M Performance:
+534.24%
1Y Performance:
+445.22%
1-Day Range:
$27.82
$28.92
1-Week Range:
$25.70
$30.60
52-Week Range:
$2.7601
$30.60
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
27.97 | 3.64B | 22.12M | -245.15M | -373.40M | -3.8546 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-26 | Initiated | Chardan Capital Markets | Buy |
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
A | What is Alumis Inc.'s debt-to-equity ratio2025 Macro Impact & Fast Moving Trade Plans - mfd.ru
Big Picture: Is Alumis Inc in a consolidation phaseWeekly Trend Report & Long-Term Growth Plans - baoquankhu1.vn
Alumis Inc stock hits all-time high at 28.34 USD By Investing.com - Investing.com India
Alumis (NASDAQ:ALMS) Sets New 52-Week HighStill a Buy? - MarketBeat
Alumis Inc stock hits all-time high at 28.34 USD - Investing.com
Alumis Inc. (ALMS): Investor Outlook Reveals 35% Upside Potential In Biotech Sector - DirectorsTalk Interviews
Risk Hedge: Is Alumis Inc gaining market shareJuly 2025 Retail & Technical Pattern Based Buy Signals - baoquankhu1.vn
Huge insider buying now at this insurance giant and 2 biotechs - MSN
Alumis Stock: Key Catalysts on the Horizon for 2026 - AD HOC NEWS
Credit Industriel ET Commercial Sells 140,000 Shares of Alumis Inc. $ALMS - MarketBeat
Why Alumis Inc. stock is trending among retail tradersJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - mfd.ru
Can Alumis Inc. expand into new markets2025 Momentum Check & Short-Term Swing Trade Alerts - mfd.ru
Alumis (NASDAQ:ALMS) Shares Up 7.2%Still a Buy? - MarketBeat
Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit - MarketBeat
Is Alumis Inc.’s growth already priced inPortfolio Growth Summary & Weekly Watchlist of Top Performers - mfd.ru
Quarterly Risk: Is Alumis Inc in a consolidation phase2025 Price Action Summary & Growth Focused Entry Reports - baoquankhu1.vn
Can Alumis Inc. ride the EV wave2025 Pullback Review & Weekly High Potential Stock Alerts - mfd.ru
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. - AOL.com
Alumis (ALMS) Valuation Check After Strong Multi‑Month Share Price Momentum - Yahoo Finance
EPS Watch: Can Alumis Inc ride the EV waveWeekly Stock Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Market Leaders: Will TWFG outperform the market in YEARTrade Analysis Report & High Win Rate Trade Alerts - baoquankhu1.vn
Alumis Ownership Shifts As Shelf Filing And Conferences Shape Outlook - Sahm
Alumis to Participate in Upcoming February Investor Conferences - The Manila Times
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Alumis and ACELYRIN announce merger in all-stock deal - MSN
Alumis (NASDAQ:ALMS) Stock Price Up 9.8%What's Next? - MarketBeat
Alumis Inc stock (ALMS) jumps again on Nasdaq — here’s what’s driving the move and what comes next - TechStock²
Why Alumis Inc. Stock Is Suddenly Powering Higher - TipRanks
Chardan highlights Alumis’s (ALMS) potential after envudeucitinib hits all phase 3 endpoints in psoriasis trials - MSN
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Top Small Cap Stocks To Watch NowJanuary 6th - MarketBeat
Chardan Highlights Alumis's (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Finviz
Chardan Highlights Alumis’s (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Insider Monkey
Alumis Inc. (NASDAQ:ALMS) Short Interest Up 93.1% in January - MarketBeat
Alumis stock hits all-time high at 27.28 USD By Investing.com - Investing.com Australia
Alumis Inc. (ALMS) Stock Analysis: A Biotech Contender With A 34.43% Potential Upside - DirectorsTalk Interviews
10 New Stocks on the Rise - Insider Monkey
Alumis (NASDAQ:ALMS) Hits New 12-Month HighStill a Buy? - MarketBeat
Alumis stock hits all-time high at 27.28 USD - Investing.com
Alumis (NASDAQ:ALMS) Trading Up 6.4%Should You Buy? - MarketBeat
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - AOL.com
Alumis (NASDAQ:ALMS) Coverage Initiated by Analysts at Chardan Capital - MarketBeat
Alumis stock reaches all-time high at 25.25 USD By Investing.com - Investing.com Australia
This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Chardan Capital initiates coverage on Alumis stock with Buy rating - Investing.com
Chardan Capital initiates coverage on Alumis stock with Buy rating By Investing.com - Investing.com Nigeria
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):